Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

• Cevostamab (Drug), also known as RO7187797: Participants will receive cevostamab as per the schedule given in the protocol.
• Pomalidomide (Drug): Pomalidomide will be administered as per the schedule given in the protocol.
• Dexamethasone (Drug): Dexamethasone will be administered as a premedication as per the schedule given in the protocol.
• Tocilizumab (Drug), also known as Actemra/RoActemra: Tocilizumab may be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.

Primary outcomes

• Overall Response Rate (ORR) as assessed by an Independent Review Committee [Up to approximately 3 years]

Secondary outcomes

• ORR, as assessed by the Investigator [Up to approximately 3 years]
• Rate of Very Good Partial Response (VGPR) or Better [Up to approximately 3 years]
• Complete Response/Stringent Complete Response (CR/sCR) Rate [Up to approximately 3 years]
• Duration of Response (DOR) [Up to approximately 3 years]
• Progression-free Survival (PFS) [Start of study treatment to first date of disease progression or death from any cause, whichever occurs first (up to approximately 3 years)]
• Overall Survival (OS) [Baseline up until death from any cause (up to approximately 3 years)]
• MRD-negative CR rate at 9 months measured in bone marrow aspirate by next-generation sequencing (NGS) [At 9 months]
• Overall MRD-Negative Complete Response Rate [Up to approximately 3 years]
• Time to Response (TTR) [Baseline up to approximately 3 years]
• Time to Better Response (TTBR) [Baseline up to approximately 3 years]
• Progression-Free Survival 2 (PFS2) [Up to approximately 3 years]
• Time to Confirmed Deterioration in the Disease Symptoms Scale of the EORTC QLQ-MY20 [Up to approximately 3 years]
• Time to Confirmed Deterioration in the Global Health Status/Quality of Life (GHS/QoL) of the EORTC QLQ-Core 30 (C30) [Up to approximately 3 years]
• Incidence and Severity of Adverse Events (AEs) [Up to approximately 3 years]
• Change From Baseline in the Disease Symptoms Scale of the EORTC QLQ-MY20 [Baseline and up to 3 years]
• Change From Baseline in the GHS/QoL of the EORTC QLQ-Core 30 (C30) [Baseline and up to 3 years]
• Change From Baseline in Fatigue as Assessed by the EORTC QLQ-C30 [Baseline and up to 3 years]
• Time to Confirmed Deterioration in Fatigue as Assessed by the EORTC QLQ-C30 [Up to approximately 3 years]
• Percentage of Participants Experiencing Clinically Meaningful Improvement in Disease Symptoms as Assessed by the EORTC QLQ-MY20 [Up to approximately 3 years]
• Percentage of Participants Experiencing Clinically Meaningful Improvement in GHS/QoL as Assessed by the EORTC QLQ-C30 [Up to approximately 3 years]
• Percentage of Participants Experiencing Clinically Meaningful Improvement in Fatigue as Assessed by the EORTC QLQ-C30 [Up to approximately 3 years]
• Percentage of Participants with Anti-Drug Antibodies (ADAs) to Cevostamab at Baseline [Baseline]
• Percentage of Participants with ADAs to Cevostamab during the Study [Up to approximately 3 years]

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to the start of administration of study treatment.
* Received one to four lines of prior therapy, including prior B-cell maturation antigen (BCMA)-targeting Chimeric Antigen Receptors (CAR) T-cell therapy
* Multiple Myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
* Is triple-class exposed, i.e. received anti- cluster of differentiation 38 (CD38) therapy, a proteasome inhibitor (PI) and lenalidomide in any prior line
* Participants must have measurable disease during screening

Exclusion Criteria:

* Known history of amyloidosis (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan)
* Plasma cell leukemia or circulating plasma cell count exceeding 500 cells/µL or 5% of the peripheral blood white cells
* History of severe allergic or anaphylactic reactions to mAb therapy (or recombinant antibody-related fusion proteins) or known hypersensitivity to any of the excipients of cevostamab
* Gastrointestinal (GI) disease that might significantly alter absorption of oral drugs
* Known active Central Nervous System (CNS) involvement, or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole-brain MRI and lumbar cytology are required.

• Clinical Trials, Study director, Hoffmann-La Roche